|
Powered by Cell Signaling Technology |
Site Information |
---|
FLSEEPPySYPTGNH SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 448785 |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Disease tissue studied: | |
Relevant cell line - cell type - tissue: |
Upstream Regulation | |
---|---|
Putative in vivo kinases: | |
Treatments: |
Downstream Regulation | |
---|---|
Effects of modification on PXN: | |
Effects of modification on biological processes: | |
Induce interaction with: |
References | |
---|---|
Kwak TK, et al. (2010) Glucosamine Treatment-mediated O-GlcNAc Modification of Paxillin Depends on Adhesion State of Rat Insulinoma INS-1 Cells. J Biol Chem 285, 36021-31
20829364 Curated Info |
|
Slack-Davis JK, et al. (2007) Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 282, 14845-52
17395594 Curated Info |
|
Ohanian V, Gatfield K, Ohanian J (2005) Role of the actin cytoskeleton in G-protein-coupled receptor activation of PYK2 and paxillin in vascular smooth muscle. Hypertension 46, 93-9
15911746 Curated Info |
|
Melendez J, et al. (2004) Cardiomyocyte apoptosis triggered by RAFTK/pyk2 via Src kinase is antagonized by paxillin. J Biol Chem 279, 53516-23
15322113 Curated Info |
|
Vallés AM, Beuvin M, Boyer B (2004) Activation of Rac1 by paxillin-Crk-DOCK180 signaling complex is antagonized by Rap1 in migrating NBT-II cells. J Biol Chem 279, 44490-6
15308668 Curated Info |